Storia in 2 fonti

Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins - Cencora (NYSE:COR)

Cencora beats third-quarter earnings and revenue estimates, raised fiscal 2026 EPS guidance and maintains its annual sales forecast.

Raccontata da

morningstar.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo17 h fa

Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins - Cencora (NYSE:COR)

Cencora beat Q3 EPS ($4.48 vs $4.35) and revenue ($84.75B, +5.1%) on OneOncology deal and specialty growth; GLP-1 squeezed margins. For healthcare tech leaders, specialty consolidation amid GLP-1 disruption signals margin compression and accelerates supply-chain digitalization investment.

originale

morningstar.com23 h fa

Cencora Reports Fiscal 2026 Third Quarter Results

Leggi questa versione → originale

Timeline cronologica

mercoledì 5 agosto 2026·morningstar.com
Cencora Reports Fiscal 2026 Third Quarter Results
Cencora Reports Fiscal 2026 Third Quarter Results
mercoledì 5 agosto 2026·benzinga.com
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins - Cencora (NYSE:COR)
Cencora beats third-quarter earnings and revenue estimates, raised fiscal 2026 EPS guidance and maintains its annual sales forecast.